<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="769">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151146</url>
  </required_header>
  <id_info>
    <org_study_id>ANJ900D1104</org_study_id>
    <nct_id>NCT05151146</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of ANJ900 Chinese Healthy Subjects</brief_title>
  <official_title>A Phase 1 Study to Investigate the Pharmacokinetics of ANJ900 (Metformin Hydrochloride Delayed-release Tablets) and the Effect of Food on the Pharmacokinetics of ANJ900 in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anji Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anji Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a Phase 1, randomised, open label, 3 way crossover study in healthy male and&#xD;
      female Chinese subjects. Subjects will participate in 3 treatment periods and will be&#xD;
      randomised in a 1:1:1 ratio to 1 of 3 treatment sequences. There will be a washout period of&#xD;
      7 days between doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 1, randomised, open label, 3 way crossover study in healthy male and&#xD;
      female Chinese subjects. Subjects will participate in 3 treatment periods and will be&#xD;
      randomised in a 1:1:1 ratio to 1 of 3 treatment sequences. There will be a washout period of&#xD;
      7 days between doses.&#xD;
&#xD;
      All subjects will receive each of the following treatments:&#xD;
&#xD;
        -  Treatment 1: A single dose of 1800 mg ANJ900 in the fasted state.&#xD;
&#xD;
        -  Treatment 2: A single dose of 1800 mg ANJ900 in the fed state.&#xD;
&#xD;
        -  Treatment 3: A single dose of 1000 mg metformin IR in the fasted state. Potential&#xD;
           subjects will be screened to assess their eligibility to enter the study within 14 days&#xD;
           prior to the first dose administration. Subjects will be admitted into the study site on&#xD;
           Days 1, 7, and 14 and will be confined to the study site until discharge on Days 3, 10,&#xD;
           and 17 respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the AUC of single oral dose of ANJ900 in healthy Chinese subjects</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize Cmax of a single oral dose of ANJ900 in healthy Chinese subjects</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the urine excretion from time zero to 24 hours post does of metformin</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of ANJ900 in healthy Chinese subjects</measure>
    <time_frame>3 weeks</time_frame>
    <description>Adverse events will be collected and reported</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ANJ900 in the fasted state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (1800 mg) of ANJ900</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANJ900 in the fed state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (1800 mg) of ANJ900</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin IR in the fasted state</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose (1000 mg) of metformin IR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANJ900</intervention_name>
    <description>Metformin hydrochloride delayed-release tablets</description>
    <arm_group_label>ANJ900 in the fasted state</arm_group_label>
    <arm_group_label>ANJ900 in the fed state</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin IR</intervention_name>
    <description>metformin hydrochloride</description>
    <arm_group_label>Metformin IR in the fasted state</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chinese males or females between 18 and 65 years of age, inclusive.&#xD;
&#xD;
          2. Body mass index between 18.5 and 28.0 kg/m2, inclusive, with a body weight &gt;50 kg&#xD;
             (males) or &gt;45 kg (females).&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12 lead ECG (including heart rate ≥50 bpm, PR interval &lt;200 ms,&#xD;
             and QRS duration &lt;120 ms), vital signs measurements (systolic blood pressure ≥90 and&#xD;
             &lt;140 mmHg and diastolic blood pressure ≥50 and &lt;90 mmHg), and clinical laboratory&#xD;
             evaluations at screening and Day -1 as assessed by the investigator (or designee).&#xD;
&#xD;
          4. Females will not be pregnant or lactating, and females of childbearing potential and&#xD;
             males will agree to use contraception as detailed in Appendix 3.&#xD;
&#xD;
          5. Able to comprehend and willing to sign an ICF, remain at the study site, and to abide&#xD;
             by the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any metabolic, allergic (eg, asthma,&#xD;
             urticaria, eczema dermatitis), dermatological, hepatic, renal, haematological,&#xD;
             pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or&#xD;
             psychiatric disorder, as determined by the investigator (or designee).&#xD;
&#xD;
          2. Malignancy within 5 years (except basal cell skin carcinoma).&#xD;
&#xD;
          3. History of a clinically significant disease that affects drug absorption, metabolism,&#xD;
             or elimination processes, as determined by the investigator (or designee), including,&#xD;
             but not limited to:&#xD;
&#xD;
               1. inflammatory bowel disease, gastritis, ulcers, bile duct stones, or internal&#xD;
                  bleeding of the gastrointestinal tract or rectum&#xD;
&#xD;
               2. gastrointestinal surgery (eg, anastomosis or bowel resection)&#xD;
&#xD;
               3. pancreatic injury or pancreatitis&#xD;
&#xD;
               4. urinary tract obstruction or difficulty passing urine.&#xD;
&#xD;
          4. History of hypoglycaemic episodes, severe unconscious hypoglycaemia, or glucose&#xD;
             metabolism disorders.&#xD;
&#xD;
          5. History of significant hypersensitivity, intolerance, or allergy to any drug compound&#xD;
             (eg, metformin), food, or other substance, unless approved by the investigator (or&#xD;
             designee).&#xD;
&#xD;
          6. Active symptoms, or a recent diagnosis of, coronavirus disease-19 (COVID-19).&#xD;
&#xD;
          7. Donation or loss of &gt;500 mL of blood within 4 weeks prior to screening.&#xD;
&#xD;
          8. Receipt of blood products within 8 weeks prior to screening.&#xD;
&#xD;
          9. Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 3 months.&#xD;
&#xD;
         10. Poor peripheral venous access or intolerant of venous blood collection.&#xD;
&#xD;
         11. Use or intend to use any prescription medications (with the exception of paracetamol&#xD;
             [≤4000 mg/day] or ibuprofen [≤2400 mg/day]) within 4 weeks or 5 half lives, whichever&#xD;
             is longer, prior to screening.&#xD;
&#xD;
         12. Use or intend to use any over the counter medications (with the exception of&#xD;
             paracetamol [≤4000 mg/day], ibuprofen [≤2400 mg/day], and topical over the counter&#xD;
             medications for external use), herbal medications, or food supplements (eg, vitamins&#xD;
             or mineral supplements) within 2 weeks or 5 half lives, whichever is longer, prior to&#xD;
             screening.&#xD;
&#xD;
         13. Fasting plasma glucose &lt;3.9 mmol/L or &gt;6.1 mmol/L at screening or Day -1.&#xD;
&#xD;
         14. Alanine aminotransferase, aspartate aminotransferase, or direct bilirubin &gt;1.5 × the&#xD;
             upper limit of normal at screening or Day -1.&#xD;
&#xD;
         15. Positive hepatitis panel, human immunodeficiency virus test, or syphilis test.&#xD;
&#xD;
         16. History of alcoholism or drug/chemical abuse within 12 months.&#xD;
&#xD;
         17. Alcohol consumption of &gt;21 units per week for males and &gt;14 units for females. One&#xD;
             unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or&#xD;
             1/6 gill (25 mL) of spirits.&#xD;
&#xD;
         18. Have consumed foods and beverages containing caffeine, xanthine, alcohol, or&#xD;
             components that affect the absorption, metabolism, and excretion of drugs (eg,&#xD;
             grapefruit or Seville oranges) within 48 hours prior to check-in.&#xD;
&#xD;
         19. Have smoked &gt;5 cigarettes or use the equivalent tobacco or nicotine containing&#xD;
             products per day in the past 3 months, or are unwilling to abstain from smoking&#xD;
             cigarettes or use the equivalent tobacco or nicotine containing products from 48 hours&#xD;
             prior to Day -1 until discharge.&#xD;
&#xD;
         20. Are unwilling to abstain from strenuous exercise from 48 hours prior to Day -1 until&#xD;
             discharge.&#xD;
&#xD;
         21. Positive alcohol breath test, urine drugs of abuse test, or urine cotinine test.&#xD;
&#xD;
         22. Subjects who, in the opinion of the investigator (or designee), should not participate&#xD;
             in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongyang Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haiyan Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Haidan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

